TABLE 1.
Patients' characteristics
| Enrolled patients (n = 223) | (%) [total] | |
|---|---|---|
| Age‐median (range) | ||
| Median | 67 (25–90) | |
| Sex, n (%) | ||
| Male | 125 | (56.0) |
| Female | 98 | (44.0) |
| Histology, n (%) | ||
| Ad including | ||
| Ad+SCLC | 158 | (70.9) |
| Ad+Sq | ||
| Sq | 36 | (16.1) |
| NSCLC | 29 | (13.0) |
| Stage‐n. (%) | ||
| IIIA,B | 55 | (24.7) |
| IVA | 62 | (27.8) |
| IVB | 106 | (47.5) |
| Targetable driver mutations | ||
| EGFR | [53] | [23.8] |
| Ex.19 deletion | 27 | (12.1) |
| L858R | 21 | (9.4) |
| T790M | 2 | (0.9) |
| L861Q | 1 | (0.5) |
| Ex.20 insertion | 2 | (0.9) |
| ALK fusion | ||
| EML4‐ALK | 9 | (4.0) |
| ROS1 fusion | [5] | [2.2] |
| CD74‐ROS1 | 1 | (0.4) |
| SDC4‐ROS1 | 2 | (0.9) |
| SLC34A2‐ROS1 | 2 | (0.9) |
| BRAF V600E | 1 | (0.4) |
| MET | [8] | [3.5] |
| Ex.14 skipping | 5 | (2.2) |
| Amplification | 3 | (1.3) |
| RET fusion | ||
| KIF5B‐RET | 4 | (1.8) |
| HER2 Ex.20 ins | 2 | (0.9) |
| KRAS | [24] | [10.8] |
| G12A | 2 | (0.9) |
| G12C | 10 | (4.5) |
| G12D | 9 | (4.1) |
| G12V | 2 | (0.9) |
| Q61H | 1 | (0.4) |
| NRAS | [2] | [0.8] |
| Q61K | 1 | (0.4) |
| Q61L | 1 | (0.4) |
| PIK3CA | [4] | [1.8] |
| E545K | 2 | (0.9) |
| H1047R | 2 | (0.9) |
| NRG1‐CD74 fusion | 1 | (0.4) |
| FGFR1 amplification | 4 | (1.8) |
| FGFR3‐TACC3 fusion | 3 | (1.3) |
Abbreviations: Ad, adenocarcinoma; Sq, squamous cell carcinoma.